Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-[(1S)-1-Benzyl-2-sulfanylethyl]-1H-imidazo[4,5-c]pyridin-5-ium
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound belongs to the class of imidazo[4,5-c]pyridines, which are organic heterocyclic compounds. These compounds may exhibit anti-inflammatory, anti-cancer, or neuroprotective effects, making them interesting candidates for the treatment of various diseases[2][4].
- Other names
- 2-[(1S)-1-Benzyl-2-sulfanylethyl]-1H-imidazo[4,5-c]pyridin-5-ium2-((1S)-1-Benzyl-2-sulfanylethyl)-1H-imidazo(4,5-c)pyridin-5-ium2-((2S)-1-phenyl-3-sulfanylpropan-2-yl)-1H-imidazo(4,5-c)pyridin-5-ium
Beyond the preview
Go deeper on 2-[(1S)-1-Benzyl-2-sulfanylethyl]-1H-imidazo[4,5-c]pyridin-5-ium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2-[(1S)-1-Benzyl-2-sulfanylethyl]-1H-imidazo[4,5-c]pyridin-5-ium.